Skip to main content
. 2017 Sep 1;7(9):e600. doi: 10.1038/bcj.2017.83

Table 2. Effect estimates from multivariable-adjusted Cox regression models for the effect of cytogenetic high-risk abnormalities on overall survival in the entire cohort and patient subgroups.

Parameter Reference HR (95% CI) P-value
Effect of multiple HRA in the entire cohort (using ISS, n=1181)
 1 HRA 0 HRA 1.65 (1.32–2.05) <0.001
 2 HRA 0 HRA 3.15 (2.00–4.96) <0.001
       
Effect of multiple HRA in the entire cohort (using R-ISS, n=1087)
 1 HRA 0 HRA 1.47 (1.16–1.86) 0.001
 2 HRA 0 HRA 2.69 (1.69–4.30) <0.001
       
Effect of specific HRA in the entire cohort (using ISS, n=1181)
 del(17p) Absence of del(17p) 1.64 (1.29–2.08) <0.001
 HRT Absence of HRT 1.78 (1.39–2.30) <0.001
       
Effect of specific HRA in the entire cohort (using R-ISS, n=1087)
 del(17p) Absence of del(17p) 1.49 (1.16–1.91) 0.002
 HRT Absence of HRT 1.62 (1.24–2.11) <0.001
       
Effect of specific additional HRA (using ISS, n=164 and n=154)
 del(17p)+HRT Isolated del(17p) 2.08 (1.19–3.63) 0.010
 del(17p)+HRT Isolated HRT 1.86 (1.07–3.22) 0.027

Abbreviations: CI, confidence interval; HR, hazard ratio; HRA, cytogenetic high-risk abnormality. HRT: High-risk translocation.

All models were adjusted for age, sex, International Staging System (ISS) or revised ISS (R-ISS) stage, and first-line therapy (immunomodulator, proteasome inhibitor, upfront autologous hematopoietic stem cell transplantation).